NEJM at ESC — Finerenone in Heart Failure for Mildly Reduced or Preserved Ejection Fraction

NEJM at ESC — Invasive versus Conservative Strategy for Older Patients with Myocardial InfarctionПодробнее

ESC 24: FINE-HEART: Finerenone in HF & CKDПодробнее

Finerenone Reduces Heart Failure Events and Cardiovascular Deaths: FINEARTS-HF trialПодробнее

Empagliflozin in Heart Failure with a Preserved Ejection FractionПодробнее

NEJM Evidence Publication in Heart Failure by Nordic Bioscience and CollaboratorsПодробнее

Finerenone in Patients With Recent Worsening Heart Failure Event: The FINEARTS-HF Trial | HFSA 2024Подробнее

Finerenone Reduces Heart Failure Events in Preserved EF Trial #journalclubПодробнее

ESC 24 Hot Line Discussion: The FINEARTS-HF TrialПодробнее

Time to Significant Benefit of Finerenone in Patients with Heart Failure | JACC | HFSA 2024Подробнее

A 73-Year-Old Woman with a Fall (Video 2) | NEJM EvidenceПодробнее

ESC 2022: FIDELITY: Finerenone in Pts With Chronic Kidney Disease | Prof Gerasimos FilippatosПодробнее

SGLT-2 Inhibitoren bei HFPEF - EMPEROR Preserved - Prof. Anker (Berlin)Подробнее

Sep 06 2024 This Week in CardiologyПодробнее

NEJM at ESC — Inflammation, Cholesterol, Lipoprotein(a) and 30-Year Cardiovascular Outcomes in WomenПодробнее

Heart Failure with Preserved Ejection FractionПодробнее

Aug 30 2024 This Week in CardiologyПодробнее

HFSA 24: Finerenone Across the Ejection Fraction Spectrum: FINEARTS-HFПодробнее

Managing Heart Failure with Preserved Ejection FractionПодробнее

241113 Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection FractionПодробнее